Monoclonal antibody specific for Omomyc, capable of suppressing Myc-induced oncogenesis.
| Inventor | Institute |
|---|---|
| Laura Soucek | Vall D'Hebron Institute Of Oncology (VHIO) |
| Cat. #: | 153657 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Apoptosis and autophagy;Cancer;Cell biology;Genetics |
| Application: | ELISA ; IHC ; IF ; WB |
| Target: | Omomyc |
| Reactivity: | Human |
| Clone: | 17 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Soucek et al. 2004. Cell Death Differ. 11(9):1038-45. PMID: 15143346. |
| Product description: | Monoclonal antibody specific for Omomyc, capable of suppressing Myc-induced oncogenesis. Omomyc is a dominant-negative allele of the proto-oncogene Myc (c-Myc). Omomyc is a mutant bHLHZip domain that sequesters Myc in complexes that are unable to bind to the E box recognition element and activate transcription but remain competent for transcriptional repression. Expression of Omomyc can induce rapid tumour regression in mouse models with little toxicity for normal tissues, acting as a suppressor of Myc-induced oncogenesis. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2a kappa |
| Target background: | Monoclonal antibody specific for Omomyc, capable of suppressing Myc-induced oncogenesis. Omomyc is a dominant-negative allele of the proto-oncogene Myc (c-Myc). Omomyc is a mutant bHLHZip domain that sequesters Myc in complexes that are unable to bind to the E box recognition element and activate transcription but remain competent for transcriptional repression. Expression of Omomyc can induce rapid tumour regression in mouse models with little toxicity for normal tissues, acting as a suppressor of Myc-induced oncogenesis. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
MassĂł-VallĂŠs D et al. 2022. Cancer Res Commun. 2(2):110-130. PMID: 36860495. Fiorentino et al. 2016. Oncotarget. 7(21):31014-28. PMID: 27105536. Soucek et al. 2013. Genes Dev. 27(5):504-13. PMID: 23475959. Soucek et al. 2004. Cell Death Differ. 11(9):1038-45. PMID: 15143346. Bibbò et al. 2024. J Control Release. 374:171-180. PMID: 39128771. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.